The non-invasive cancer diagnostics market is projected to grow at an annualized rate of ~20%, till 2030
Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-InvasiveCancer DiagnosticsMarket (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such asCTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.” covering key aspects of the industry’s evolution andidentifying potential future growth opportunities.
To order this 350+ pagereport, which features 150+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Key Market Insights
§ Presently, nearly 300non-invasive diagnostic tests, designed for the detection of various types ofcancers, are either already available in the market or under development acrossthe world
§ Several moderndiagnostic tests claim to be capable of offering results in relatively shorttime periods, thereby, facilitating early diagnosis that is particularlybeneficial in the treatment of different types of cancers
§ Over time, big pharmaplayers have initiated product development programs, having investedsignificant capital, time and effort, on non-invasive diagnostic solutions foruse across different oncological indications
§ Investors, havingrealized the untapped opportunity within this emerging segment of the cancerdiagnostics market, have invested over USD 3 billion across 120 instances inthe period between 2015 and 2019
§ The growing interest in this field is also reflected in the partnershipactivity; deals inked in the recent past are focused on a diverse range oftumor markers, involving both international and indigenous stakeholders
§ The projected futureopportunity is anticipated to be driven by increasing patient population anddistributed across various disease indications and application areas across keygeographies
§ These tests are capable of detecting diverse tumor markers that cater tothe needs of different stakeholders; in fact, opinions of industry expertsconfirm the vast potential of liquid biopsies in disease diagnosis / monitoring
For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Table of Contents
1. PREFACE
1.1. Scopeof the Report
1.2. ResearchMethodology
1.3. ChapterOutlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. CancerStatistics and Burden of the Disease
3.3. Importanceof Early Cancer Detection
3.4. CancerScreening and Diagnosis
3.5. ConventionalInvasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. FineNeedle Aspiration Biopsy
3.5.1.2. CoreNeedle Biopsy
3.5.1.3. Vacuum-AssistedBiopsy
3.5.1.4. Image-GuidedBiopsy
PressRelease: Variation 2 (Format 3)
3.5.1.5. SentinelNode Biopsy
3.5.1.6. SurgicalBiopsy
3.5.1.7. EndoscopicBiopsy
3.5.1.8. BoneMarrow Biopsy
3.5.2. Endoscopy
3.6. Needfor Non-Invasive Approaches
3.7. LiquidBiopsy: Diagnosing Circulating Biomarkers
3.7.1. CirculatingTumor Cells
3.7.2. CirculatingTumor DNA
3.7.3. Exosomes
3.8. Costsand Benefits Associated with Liquid Biopsy and Non-Invasive Tests
3.9. EmergingTrends in Intellectual Property Related to Non-Invasive Cancer Diagnostics
3.10. ChallengesAssociated with Non-Invasive Cancer Diagnostics
3.11. FuturePerspectives
4. NON-INVASIVECANCER SCREENING AND DIAGNOSIS
4.1. ChapterOverview
4.2. DiagnosticImaging
4.2.1. MagneticResonance Imaging (MRI)
4.2.2. Mammography
4.2.3. BoneScan
4.2.4. ComputerizedTomography (CT) Scan
4.2.5. IntegratedPositron Emission Tomography (PET)-CT Scan
4.2.6. Ultrasound
4.2.7. X-rayRadiography (Barium Enema)
4.3. ScreeningAssays
4.3.1. CirculatingTumor Marker Test
4.3.2. DigitalRectal Exam (DRE)
4.3.3. FecalOccult Blood Test (FOBT)
4.3.4. MultigatedAcquisition (MUGA) Scan
4.3.5. PapanicolaouTest and Human Papilloma Virus Test
4.4. AdvancedNon-Invasive Approaches
4.4.1. Cytogenetic/ Gene Expression Studies
4.4.2. MolecularSignature-based Non-Invasive Methods
4.4.3. Saliva-basedOral Cancer Diagnostics
4.4.4. VitalStaining
4.4.5. OpticalBiopsy
4.4.6. OtherDiagnostic Techniques
5. MARKETLANDSCAPE
5.1. ChapterOverview
5.2. LiquidBiopsy Products: List of Developers
5.2.1. Analysisby Year of Establishment
5.2.2. Analysisby Company Size and Geographical Location
5.2.3. LeadingPlayers
5.2.4. Analysisby Geography
5.3. LiquidBiopsy Products: List of Available / Under Development Products
5.3.1. Analysisby Status of Development
5.3.2. Analysisby Type of Product
5.3.3. Analysisby Application Area
PressRelease: Variation 2 (Format 3)
5.3.4. Analysisby Target Cancer Indication
5.3.5. Analysisby Type of Tumor Marker
5.3.6. Analysisby End User
5.3.7. Analysisby Turnaround Time
5.4. LiquidBiopsy Products: List of Other Products, Kits and Consumables
5.5. LiquidBiopsy Products: List of Contract Service Providers
6. COMPANYPROFILES
6.1. ChapterOverview
6.2. AmoyDiagnostics
6.2.1. CompanyOverview
6.2.2. FinancialInformation
6.2.3. LiquidBiopsy Product Portfolio
6.2.4. RecentDevelopments and Future Outlook
6.3. DiaCarta
6.3.1. CompanyOverview
6.3.2. LiquidBiopsy Product Portfolio
6.3.3. RecentDevelopments and Future Outlook
6.4. HaploX
6.4.1. CompanyOverview
6.4.2. LiquidBiopsy Product Portfolio
6.4.3. RecentDevelopments and Future Outlook
6.5. NeoGenomics
6.5.1. CompanyOverview
6.5.2. FinancialInformation
6.5.3. LiquidBiopsy Product Portfolio
6.5.4. RecentDevelopments and Future Outlook
6.6. QIAGEN
6.6.1. CompanyOverview
6.6.2. FinancialInformation
6.6.3. LiquidBiopsy Product Portfolio
6.6.4. RecentDevelopments and Future Outlook
6.7. SwiftBiosciences
6.7.1. CompanyOverview
6.7.2. LiquidBiopsy Product Portfolio
6.7.3. RecentDevelopments and Future Outlook
6.8. SysmexInostics
6.8.1. CompanyOverview
6.8.2. LiquidBiopsy Product Portfolio
6.8.3. RecentDevelopments and Future Outlook
6.9. ThermoFisher Scientific
6.9.1. CompanyOverview
6.9.2. FinancialInformation
6.9.3. LiquidBiopsy Product Portfolio
6.9.4. RecentDevelopments and Future Outlook
7. PARTNERSHIPSAND COLLABORATIONS
7.1. ChapterOverview
PressRelease: Variation 2 (Format 3)
7.2. PartnershipModels
7.3. Listof Partnerships and Collaborations
7.3.1. Analysisby Year of Partnership
7.3.2. Analysisby Type of Partnership
7.3.3. Analysisby Type of Tumor Marker
7.3.4. Analysisby Target Cancer Indication
7.3.5. Analysisby Type of Partner
7.3.6. MostActive Players: Analysis by Number of Partnerships
7.3.7. RegionalAnalysis
7.3.7.1. Intercontinentaland Intracontinental Agreements
8. FUNDINGAND INVESTMENT ANALYSIS
8.1. ChapterOverview
8.2. Typesof Funding
8.3. Listof Funding and Investment Instances
8.3.1. Analysisby Number of Funding Instances
8.3.2. Analysisby Amount Invested
8.3.3. Analysisby Type of Funding
8.3.4. Analysisby Target Cancer Indication
8.3.5. Analysisby Type of Tumor Marker
8.3.6. MostActive Players: Analysis by Amount Invested
8.3.7. MostActive Investors: Analysis by Number of Funding Instances
8.3.8. RegionalAnalysis by Amount Invested
8.4. ConcludingRemarks
9. LIQUIDBIOPSY: INITIATIVES OF BIG PHARMA PLAYERS
9.1. ChapterOverview
9.2. TopPharmaceutical Companies
9.2.1. Analysisby Status of Development
9.2.2. Analysisby Type of Tumor Marker
9.2.3. Analysisby Application Area
9.2.4. Analysisby Target Cancer Indication
10. KEYACQUISITION TARGETS
10.1. ChapterOverview
10.2. Scopeand Methodology
10.3. ScoringCriteria and Key Assumptions
10.4. PotentialStrategic Acquisition Targets in North America
10.5. PotentialStrategic Acquisition Targets in Europe
10.6. PotentialStrategic Acquisition Targets in Asia-Pacific / Rest of the World
10.7. ConcludingRemarks
11. OTHERNON-INVASIVE CANCER DIAGNOSTICS
11.1. ChapterOverview
11.2. Non-Blood-basedBiomarker Detection Tests
11.3. FOBTand Fecal Immunochemical Tests (FIT)
11.4. PigmentedLesion Assays
11.5. StoolDNA (sDNA)-based Tests
11.6. VolatileOrganic Compound (VOC) Detection Tests
11.7. OtherNon-Invasive Cancer Diagnostics: Market Landscape
12. MARKETSIZING AND OPPORTUNITY ANALYSIS
12.1. ChapterOverview
12.2. KeyAssumptions and Forecast Methodology
PressRelease: Variation 2 (Format 3)
12.3. GlobalNon-Invasive Cancer Diagnostics Market, 2019-2030
12.3.1. GlobalLiquid Biopsy Market, 2019-2030
12.3.1.1. Global Liquid Biopsy Market: Distribution byApplication Area, 2019-2030
12.3.1.1.1. GlobalLiquid Biopsy Market for Early Diagnosis, 2019-2030
12.3.1.1.2. GlobalLiquid Biopsy Market for Patient Monitoring, 2019-2030
12.3.1.1.3. GlobalLiquid Biopsy Market for Recurrence Monitoring, 2019-2030
12.3.1.2. Global Liquid Biopsy Market: Distribution byTarget Cancer Indication, 2019-2030
12.3.1.2.1. GlobalLiquid Biopsy Market for Breast Cancer, 2019-2030
12.3.1.2.2. GlobalLiquid Biopsy Market for Lung Cancer, 2019-2030
12.3.1.2.3. GlobalLiquid Biopsy Market for Colorectal Cancer, 2019-2030
12.3.1.2.4. GlobalLiquid Biopsy Market for Prostate Cancer, 2019-2030
12.3.1.2.5. GlobalLiquid Biopsy Market for Bladder Cancer, 2019-2030
12.3.1.2.6. GlobalLiquid Biopsy Market for Melanoma, 2019-2030
12.3.1.2.7. GlobalLiquid Biopsy Market for Gastric Cancer, 2019-2030
12.3.1.2.8. GlobalLiquid Biopsy Market for Pancreatic Cancer, 2019-2030
12.3.1.2.9. GlobalLiquid Biopsy Market for Ovarian Cancer, 2019-2030
12.3.1.3. Global Liquid Biopsy Market: Distribution byType of Tumor Marker, 2019-2030
12.3.1.3.1. GlobalLiquid Biopsy Market for ctDNA, 2019-2030
12.3.1.3.2. GlobalLiquid Biopsy Market for cfDNA, 2019-2030
12.3.1.3.3. GlobalLiquid Biopsy Market for CTCs, 2019-2030
12.3.1.3.4. GlobalLiquid Biopsy Market for Exosomes, 2019-2030
12.3.1.3.5. GlobalLiquid Biopsy Market for Other Tumor Markers, 2019-2030
12.3.1.4. Global Liquid Biopsy Market: Distribution byType of Analyte, 2019-2030
12.3.1.4.1. GlobalLiquid Biopsy Market for Blood, 2019-2030
12.3.1.4.2. GlobalLiquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)
12.3.1.5. Global Liquid Biopsy Market: Distribution byEnd User, 2019-2030
12.3.1.5.1. GlobalLiquid Biopsy Market for Hospitals, 2019-2030
12.3.1.5.2. GlobalLiquid Biopsy Market for Research Institutes, 2019-2030
12.3.1.5.3. GlobalLiquid Biopsy Market for Other End Users, 2019-2030
12.3.1.6. Global Liquid Biopsy Market: Distribution byGeography, 2019-2030
12.3.1.6.1. LiquidBiopsy Market in the US, 2019-2030
12.3.1.6.2. LiquidBiopsy Market in the UK, 2019-2030
12.3.1.6.3. LiquidBiopsy Market in Germany, 2019-2030
12.3.1.6.4. LiquidBiopsy Market in France, 2019-2030
12.3.1.6.5. LiquidBiopsy Market in Italy, 2019-2030
12.3.1.6.6. LiquidBiopsy Market in Spain, 2019-2030
12.3.1.6.7. Liquid Biopsy Market in Japan, 2019-2030
12.3.1.6.8. LiquidBiopsy Market in China, 2019-2030
12.3.1.6.9. LiquidBiopsy Market in India, 2019-2030
12.3.1.6.10. Liquid Biopsy Market in Australia, 2019-2030
12.3.2. OtherNon-Invasive Cancer Diagnostics Market Forecast, 2019-2030
13. SURVEYINSIGHTS
13.1. ChapterOverview
13.2. CompanySpecifics of Respondents
13.3. Designationof Respondents
13.4. Typeof Product Portfolio
13.5. Typesof Products / Services Offered
13.6. ApplicationArea
PressRelease: Variation 2 (Format 3)
13.7. Statusof Development of the Products
13.8. LikelyMarket Size
14. CONCLUSION
14.1. Timely Disease Detection and SubsequentMonitoring are Critical Elements of Patient Care
in the Fieldof Oncology
14.2. Introductionof Sophisticated Molecular Diagnostics has Facilitated Better Cancer
Management
14.3. LiquidBiopsy has Emerged as a Reliable Alternative to the Invasive Methods ofDiagnosis
14.4. TheVersatile and Patient Friendly Nature of these Diagnostic Tools Cater to a WideRange
ofApplications
14.5. TheInterest is Gradually Rising with Participation of Several Start-ups AcrossDifferent
Geographies
14.6. InAddition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further
Strengthen theOngoing Innovation
14.7. RisingVenture Capital Support is Indicative of a Lucrative Future Potential
14.8. PrimarilyLed by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged
as aMulti-Billion Dollar Market
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Interview Transcript: ShibichakravarthyKannan, Founder & Chief Executive Officer,
TheranosisLife Sciences
15.3. Interview Transcript: Anton Iliuk,President and Chief Technology Officer, Tymora Analytical
Operations
15.4. Interview Transcript: Peter French,Strategic Technology Advisor, Sienna Cancer
Diagnostics
15.5. Interview Transcript: Joachim Fluhrer,Founder and Medical Director, Genostics
15.6. Interview Transcript: Brad Walsh, ChiefExecutive Officer, Minomic International
15.7. Interview Transcript: Catalina Vasquez,Chief Operating Officer, Nanostics
15.8. Interview Transcript: Burkhard Jansen,Chief Medical Officer, DermTech
15.9. Interview Transcript: Frank Szczepanski,President and CEO, IVDiagnostics
15.10. Interview Transcript: Riccardo Razzini,Sales and Marketing Manager, LCM Genect
15.11. Interview Transcript: Nathalie Bernard,Marketing Director, OncoDNA
15.12. Interview Transcript: Abizar Lakdawalla,Founder, Proxeom
15.13. Interview Transcript: Mark Li, CEO,Resolution Bioscience
15.14. Interview Transcript: Christer Ericsson,Chief Scientific Officer, iCellate Medical
15.15. Interview Transcript: Philippe Nore, CEOand Co-founder, MiNDERA
15.16. Interview Transcript: Jake Micallef,Chief Scientific Officer, VolitionRx
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
